摘要
The development of domestic biogenerics to replace imported drugs is among the main goals of the Pharma-2020 strategy. Insulin glargine, a therapeutic polypeptide with sustained glycolytic activity, is one of the most important biogenerics. A systematic approach to the rational design of biotechnology processes for producing pharmaceuticals such as recombinant proteins was described. Use of a systematic approach using insulin glargine as an example facilitated its rapid and effective production technology development.
- 出版日期2015-3